Arrowhead Research | ARWR - Ebitda


Arrowhead Research reported $64.2M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Agios Pharmaceuticals USD -125.8M 20.45M Jun/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
Incyte USD 581.52M 358.87M Jun/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Ligand Pharmaceuticals USD 20.9M 61.44M Jun/2025
Merck USD 8.39B 1.97B Sep/2025
Moderna USD -208M 552M Sep/2025
Novartis USD 5.88B 290M Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
TG Therapeutics USD 37.7M 25.41M Jun/2025
Ultragenyx Pharmaceutical USD -91.34M 35.09M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025
Xencor USD -30.52M 6.39M Jun/2025